A dose of 1,000 mg probenecid was administered orally to 14 human volunteers in order to quantify the maximal rate of formation and excretion of probenecid acyl glucuronide in the urine. Probenecid showed dose-dependent pharmacokinetics. Plasma protein binding of probenecid was high, being somewhat higher in males (90.7±1.4%) than in females (87.9±1.4%; p=0.0019). It was shown that probenecid is metabolized by cytochrome P-450 into at least two phase I metabolites. Each of the metabolites accounted for less than 12% of the dose administered; the main metabolite probenecid acyl glucuronide, representing 42.9±13.2% of the dose, was only present in urine and not in plasma. The renal excretion rate-time profile of probenecid acyl glucuronide showed a plateau value in the presence of an acidic urine pH. This plateau value was maintained for about 10 h at the dose of 1,000 mg. The height of the plateau value depended on the individual and varied between 250 and 800μg/min (15–50 mg/h). It was inferred that probenecid acyl glucuronide is formed in the kidney during blood-to-lumen passage through the tubular cells. We conclude that the plateau value in the renal excretion rate of probenecid glucuronide reflects itsV max of formation.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Beyer KH. New concept of competitive inhibition of the renal tubular excretion of penicillin. Science 1947;105:94–5.
Beyer KH. Functional characteristics of renal transport mechanisms. Pharmacol Rev 1950;2:227–80.
Beyer KH, Russo HF, Tillson EK, Miller AK, Verwey WF, Gass SR. Benemid,p-(di-n-propylsulphamoyl)-benzoic acid: its renal affinity and its elimination. Am J Physiol 1951:166:625–40.
Beyer KH. Factors basic to the development of useful inhibitors of renal transport mechanisms. Arch Int Pharmacodyn 1954;48:97–117.
Gutman AB, Yü TF. Renal function in gout, with a commentary on the renal regulation of urate excretion, and the role of the kidneys in the pathogenesis of gout. Am J Med 1957;23:600–25.
Weiner IM, Washington JA, Mudge GH. On the mechanism of action of probenecid on renal tubular secretion. Bull Johns Hopkins Hosp 1960;106:333–46.
Israeli ZH, Perel JM, Cunningham RF, Dayton PG, Yü TF, Gutman AB,et al. Metabolites of probenecid. Chemical, physical and pharmacological studies. J Med Chem 1972;15:709–13.
Dayton PG, Perel JM, Cunningham RF, Israeli ZH, Weiner IM. Studies of the fate of metabolites and analogs of probenecid. Drug Metab Dispos 1973;1:742–51.
Cunningham RF, Israeli ZH, Dayton PG. Clinical pharmacokinetics of probenecid. Clin Pharmacokin 1981;13(5): 135–51.
Dayton PG, Yü TF, Chen W, Berger L, West LA, Gutman AB. The physiological disposition of probenecid, including renal clearance, in man, studied by an improved method for its estimation in biological material. J Pharmacol Exp Ther 1963;140:278–85.
Ho JC, Conway WD, Melethil S. Probenecid disposition by parallel Michaelis-Menten and dose dependent pseudo first order processes. J Pharm Sci 1986;75:664–8.
Upton RA, Buskin JN, Williams RL, Holford NHG, Riegelman S. Negligible excretion of unchanged ketoprofen, naproxen and probenecid in urine. J Pharm Sci 1980;69:1254–7.
Guarino AM, Schanker LS. Biliary excretion of probenecid and its glucuronide. J Pharmacol Exp Ther 1968;164:387–95.
Perel JM, Dayton PG, Yü TF, Gutman AB. Studies of the renal excretion of probenecid acyl glucuronidation in man. Eur J Clin Pharmacol 1971;3:106–12.
Tillson EK, Schuchardt GS, Fishman JK, Beyer KH. The determination of probenecid (Benemid) in body fluids. J Pharmacol Exp Ther 1954;111:385–403.
Eggers NJ, Doust K. Isolation and identification of probenecid acyl glucuronide. J Pharm Pharmacol 1981;33:123–4.
Dickinson RG, Hooper WD, Eadie MJ. pH Dependent rearrangement of the biosynthetic ester glucuronide of valproic acid toβ-glucuronidase-resistant forms. Drug Metab Dispos 1984; 12:247–52.
Faed EM. Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metab Rev 1984;15:1213–49.
Hasegawa J, Smith PC, Benet LZ. Apparent intramolecular acyl migration of zomepirac glucuronide. Drug Metab Dispos 1982;10:469–73.
Vree TB, Beneken Kolmer EWJ. Direct measurement of probenecid and its glucuronide conjugate by means of high performance liquid chromatography in plasma and urine of humans. Pharm Weekbl [Sci] 1992;14(3):83–7.
Vree TB, Beneken Kolmer EWJ, Wuis EW, Hekster YA. Capacity-limited renal glucuronidation of probenecid by humans. A pilotV max-finding study. Pharm Weekbl [Sci] 1992;14(5):325–31.
Jaffé M. Untersuchungen über die Entstehung des Kreatins im Organismus. Hoppe Seylers Z Physiol Chem 1906;48:430–68.
Proost JH, Meijer DKF. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992;22:155–63.
SAS user's guide. Basics 1982 edition. Cary: SAS Institute, 1982.
Vree TB, Van den Biggelaar-Martea M, Verwey-van Wissen CPWGM. Determination of naproxen and its metabolite O-desmethylnaproxen with their acyl glucuronides in human plasma and urine by means of direct gradient high-performance liquid chromatography. J Chromatogr Biomed Appl 1992;578:239–49.
About this article
Cite this article
Vree, T.B., Van Ewijk-Beneken Kolmer, E.W.J., Wuis, E.W. et al. Interindividual variation in the capacity-limited renal glucuronidation of probenecid by humans. Pharm World Sci 15, 197–202 (1993). https://doi.org/10.1007/BF01880626
- Clearance, renal
- Protein binding